A leading AI-powered health tech company, Anumana, has partnered with InfoBionic.Ai, a digital health-focused company specializing in remote cardiac monitoring and diagnostic technology, to develop and commercialize revolutionary remote cardiac monitoring solutions.
According to a joint press release, the initiative combines Anumana’s breakthrough ECG-AI™ technology (developed and tested in collaboration with Mayo Clinic) with InfoBionic.Ai’s MoMe ARC® cardiac monitoring platforms to detect cardiac illnesses earlier in remote patient monitoring settings.
With early disease detection, the patients can receive timely intervention and personalized care, improving the therapy outcomes.
The new partnership between the two tech giants unlocks a new vista of opportunities in which both companies stand to benefit.
By combining InfoBionic.Ai’s proven capabilities in developing remote monitoring solutions, with Anumana’s innovative AI-powered algorithms for detecting low ejection fraction (LEF), the two companies aim to equip healthcare professionals with advanced tools to detect underlying cardiac diseases in advance.
The agreement comes amid growing partnerships between healthcare technology platforms and AI-focusing companies to help revolutionize nearly all aspects of care, drug delivery, clinical workflow, patient management, monitoring and more.
As part of the agreement, the two companies will work together to advance their integrated solutions to clinical validation and seek necessary regulatory approvals for commercialization.
So far, four of Anumana’s algorithms: low ejection fraction, cardiac amyloidosis, pulmonary hypertension, and hyperkalemia, have received the FDA’s Breakthrough Device Designation.
The company’s ECG-AI platform also won the 2024 MedTech Breakthrough Award under the category of “Best New Technology Solution- Cardiology.”
Anumana’s ECG-AI technology has also proven its capability of adapting to lower-lead ECG devices without compromising performance. On the other hand, InfoBionic.Ai’s MoMe ARC is the first 6-lead FDA-cleared platform using cutting-edge AI analysis and business intelligence.
